TD ASSET MANAGEMENT INC - FATE THERAPEUTICS INC ownership

FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 79 filers reported holding FATE THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
TD ASSET MANAGEMENT INC ownership history of FATE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$300,302
-10.9%
141,652
+100.0%
0.00%
Q2 2023$337,132
-16.5%
70,8260.0%0.00%
Q1 2023$403,708
-43.5%
70,8260.0%0.00%
-100.0%
Q4 2022$714,634
-64.3%
70,826
-20.9%
0.00%
-66.7%
Q3 2022$2,000,000
-28.1%
89,526
-20.2%
0.00%0.0%
Q2 2022$2,781,000
-39.0%
112,240
-4.5%
0.00%
-25.0%
Q1 2022$4,559,000
-27.0%
117,580
+10.2%
0.00%
-20.0%
Q4 2021$6,242,000
-1.3%
106,6810.0%0.01%
-28.6%
Q3 2021$6,323,000
-13.0%
106,681
+21.5%
0.01%0.0%
Q2 2021$7,271,000
-0.5%
87,810
-0.9%
0.01%
-12.5%
Q1 2021$7,306,000
-9.9%
88,610
-0.6%
0.01%
-20.0%
Q4 2020$8,109,000
+247.0%
89,180
+52.5%
0.01%
+233.3%
Q3 2020$2,337,000
+98.1%
58,480
+70.1%
0.00%
+50.0%
Q2 2020$1,180,000
+70.8%
34,380
+10.5%
0.00%
+100.0%
Q1 2020$691,000
+0.9%
31,109
-11.1%
0.00%0.0%
Q4 2019$685,000
+4.7%
35,009
-16.9%
0.00%0.0%
Q3 2019$654,000
-23.1%
42,109
+0.5%
0.00%0.0%
Q2 2019$851,000
+20.5%
41,909
+4.2%
0.00%0.0%
Q1 2019$706,000
+24.5%
40,209
-9.0%
0.00%0.0%
Q4 2018$567,000
-15.5%
44,209
+7.3%
0.00%0.0%
Q3 2018$671,000
+67.3%
41,185
+16.3%
0.00%0.0%
Q2 2018$401,000
-1.2%
35,400
-14.9%
0.00%0.0%
Q1 2018$406,000
+256.1%
41,600
+122.8%
0.00%
Q4 2017$114,00018,6680.00%
Other shareholders
FATE THERAPEUTICS INC shareholders Q4 2017
NameSharesValueWeighting ↓
ARCH Venture Management, LLC 2,073,190$26,599,00026.59%
Polaris Venture Management Co. V, L.L.C. 1,823,186$23,391,00024.97%
Casdin Capital, LLC 2,550,000$32,717,0005.60%
Redmile Group, LLC 10,359,666$132,915,0005.34%
Aquilo Capital Management, LLC 697,096$8,944,0004.33%
Eversept Partners, LP 165,000$2,116,9501.15%
Artal Group S.A. 2,150,000$27,585,0001.02%
AlpInvest Partners B.V. 26,925$345,0000.99%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 1,654,865$21,232,0000.85%
Lisanti Capital Growth, LLC 142,760$1,832,0000.74%
View complete list of FATE THERAPEUTICS INC shareholders